145 related articles for article (PubMed ID: 23641864)
1. Imidafenacin for the treatment of overactive bladder.
Leone Roberti Maggiore U; Scala C; Venturini PL; Ferrero S
Expert Opin Pharmacother; 2013 Jul; 14(10):1383-97. PubMed ID: 23641864
[TBL] [Abstract][Full Text] [Related]
2. Randomized, open-label, tolterodine-controlled, comparative study of the novel antimuscarinic agent imidafenacin in patients with overactive bladder.
Pushkar DY; Kasyan GR; Kolontarev KB; Sharvadze GG; Mukhametshina EI
Neurourol Urodyn; 2019 Jun; 38(5):1313-1321. PubMed ID: 30888691
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and toxicity of antimuscarinic drugs for overactive bladder treatment in females.
Leone Roberti Maggiore U; Salvatore S; Alessandri F; Remorgida V; Origoni M; Candiani M; Venturini PL; Ferrero S
Expert Opin Drug Metab Toxicol; 2012 Nov; 8(11):1387-408. PubMed ID: 22871042
[TBL] [Abstract][Full Text] [Related]
4. Urinary Excretion Contributes to Long-Lasting Blockade of Bladder Muscarinic Receptors by Imidafenacin: Effect of Bilateral Ureteral Ligation.
Ito Y; Kuraoka S; Endo S; Takahashi A; Onoue S; Yamada S
J Pharmacol Exp Ther; 2017 Jan; 360(1):69-74. PubMed ID: 27831487
[TBL] [Abstract][Full Text] [Related]
5. Basic and clinical aspects of antimuscarinic agents used to treat overactive bladder.
Yamada S; Ito Y; Nishijima S; Kadekawa K; Sugaya K
Pharmacol Ther; 2018 Sep; 189():130-148. PubMed ID: 29709423
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological effects of imidafenacin (KRP-197/ONO-8025), a new bladder selective anti-cholinergic agent, in rats. Comparison of effects on urinary bladder capacity and contraction, salivary secretion and performance in the Morris water maze task.
Kobayashi F; Yageta Y; Yamazaki T; Wakabayashi E; Inoue M; Segawa M; Matsuzawa S
Arzneimittelforschung; 2007; 57(3):147-54. PubMed ID: 17469649
[TBL] [Abstract][Full Text] [Related]
7. Long-term safety, tolerability, and efficacy of the novel anti-muscarinic agent imidafenacin in Japanese patients with overactive bladder.
Homma Y; Yamaguchi O
Int J Urol; 2008 Oct; 15(11):986-91. PubMed ID: 18761536
[TBL] [Abstract][Full Text] [Related]
8. Effect of imidafenacin on nocturia and sleep disorder in patients with overactive bladder.
Wada N; Watanabe M; Kita M; Matsumoto S; Osanai H; Yamaguchi S; Numata A; Fujisawa M; Saga Y; Hou K; Iuchi H; Niibori D; Kura T; Taniguchi A; Kunieda M; Nakata Y; Kakizaki H
Urol Int; 2012; 89(2):215-21. PubMed ID: 22832092
[TBL] [Abstract][Full Text] [Related]
9. Effects of imidafenacin (KRP-197/ONO-8025), a new anti-cholinergic agent, on muscarinic acetylcholine receptors. High affinities for M3 and M1 receptor subtypes and selectivity for urinary bladder over salivary gland.
Kobayashi F; Yageta Y; Segawa M; Matsuzawa S
Arzneimittelforschung; 2007; 57(2):92-100. PubMed ID: 17396619
[TBL] [Abstract][Full Text] [Related]
10. Selective binding of bladder muscarinic receptors in relation to the pharmacokinetics of a novel antimuscarinic agent, imidafenacin, to treat overactive bladder.
Yamada S; Seki M; Ogoda M; Fukata A; Nakamura M; Ito Y
J Pharmacol Exp Ther; 2011 Feb; 336(2):365-71. PubMed ID: 21047953
[TBL] [Abstract][Full Text] [Related]
11. Clinical efficacy and safety of mirabegron and imidafenacin in women with overactive bladder: A randomized crossover study (the MICRO study).
Torimoto K; Matsushita C; Yamada A; Goto D; Matsumoto Y; Hosokawa Y; Miyake M; Aoki K; Hirayama A; Tanaka N; Fujimoto K
Neurourol Urodyn; 2017 Apr; 36(4):1097-1103. PubMed ID: 27265880
[TBL] [Abstract][Full Text] [Related]
12. The cost-effectiveness of solifenacin vs fesoterodine, oxybutynin immediate-release, propiverine, tolterodine extended-release and tolterodine immediate-release in the treatment of patients with overactive bladder in the UK National Health Service.
Cardozo L; Thorpe A; Warner J; Sidhu M
BJU Int; 2010 Aug; 106(4):506-14. PubMed ID: 20132203
[TBL] [Abstract][Full Text] [Related]
13. Noninvasive evaluation of brain muscarinic receptor occupancy of oxybutynin, darifenacin and imidafenacin in rats by positron emission tomography.
Yoshida A; Maruyama S; Fukumoto D; Tsukada H; Ito Y; Yamada S
Life Sci; 2010 Jul; 87(5-6):175-80. PubMed ID: 20598326
[TBL] [Abstract][Full Text] [Related]
14. Effects of vibegron, a novel β
Maruyama I; Yamamoto S; Tsuchioka K; Yamazaki T
Eur J Pharmacol; 2020 Jul; 878():173096. PubMed ID: 32259514
[TBL] [Abstract][Full Text] [Related]
15. Comparisons of the therapeutic safety of seven oral antimuscarinic drugs in patients with overactive bladder: a network meta-analysis.
Yang N; Wu Q; Xu F; Zhang X
J Int Med Res; 2021 Sep; 49(9):3000605211042994. PubMed ID: 34510960
[TBL] [Abstract][Full Text] [Related]
16. A randomised, double-blind, parallel design, multi-institutional, non-inferiority phase IV trial of imidafenacin versus fesoterodine for overactive bladder.
Lee KS; Park B; Kim JH; Kim HG; Seo JT; Lee JG; Jang Y; Choo MS
Int J Clin Pract; 2013 Dec; 67(12):1317-26. PubMed ID: 24246210
[TBL] [Abstract][Full Text] [Related]
17. Comparison of mirabegron and imidafenacin for efficacy and safety in Japanese female patients with overactive bladder: A randomized controlled trial (COMFORT study).
Otsuka A; Kageyama S; Suzuki T; Matsumoto R; Nagae H; Kitagawa M; Furuse H; Ozono S
Int J Urol; 2016 Dec; 23(12):1016-1023. PubMed ID: 27686226
[TBL] [Abstract][Full Text] [Related]
18. Fesoterodine clinical efficacy and safety for the treatment of overactive bladder in relation to patient profiles: a systematic review.
Chapple C; Oelke M; Kaplan SA; Scholfield D; Arumi D; Wagg AS
Curr Med Res Opin; 2015 Jun; 31(6):1201-43. PubMed ID: 25798911
[TBL] [Abstract][Full Text] [Related]
19. Mirabegron in the treatment of overactive bladder.
Leone Roberti Maggiore U; Cardozo L; Ferrero S; Sileo F; Cola A; Del Deo F; Torella M; Colacurci N; Candiani M; Salvatore S
Expert Opin Pharmacother; 2014 Apr; 15(6):873-87. PubMed ID: 24646053
[TBL] [Abstract][Full Text] [Related]
20. [Pharmacological and clinical profile of imidafenacin developed as a new therapeutic agent for overactive bladder].
Uno T; Kobayashi F; Ogata A; Konomi T
Nihon Yakurigaku Zasshi; 2008 May; 131(5):379-87. PubMed ID: 18480570
[No Abstract] [Full Text] [Related]
[Next] [New Search]
